$3.03
-0.73 (-19.41%)
Open$3.58
Previous Close$3.76
Day High$3.58
Day Low$2.94
52W High$161.00
52W Low—
Volume—
Avg Volume6.07M
Market Cap3.88M
P/E Ratio—
EPS$-200.08
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+20.5% upside
Current
$3.03
$3.03
Target
$3.65
$3.65
$2.40
$3.65 avg
$4.80
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 24.25M | 335.8K | 347.3K |
| Net Income | -417,296,962 | 43.0K | 52.4K |
| Profit Margin | -1,721.0% | 12.8% | 15.1% |
| EBITDA | -696,548,135 | 73.2K | 78.8K |
| Free Cash Flow | — | 45.7K | 64.8K |
| Rev Growth | — | +0.6% | +12.6% |
| Debt/Equity | — | 0.59 | 0.52 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |